Vaccines: Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine?. Flemming Alexandra. Nature reviews. Drug discovery . 2012Flemming A. Vaccines: Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine? Nat Rev Drug Discov. 2012; 11 :748–749. doi: 10.1038/nrd3854.
The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle(LNP) as a vaccine. We observe ...
Herein, we undertake extensive invitro and invivo assessments to explore recombination between SAM vaccine and a wide selection of alphaviruses and a coronavirus. SAM vaccines were found to effectively limit alphavirus co-infection through superinfection exclusion, althoug...
Self-amplifying RNA (saRNA) vaccine technology as well as mRNA technology enable rapid and scalable vaccine production, requiring minimal amounts of RNA per dose. In mice, saRNAs have been shown to confer equivalent protection against influenza virus as mRNA vaccines, but at much lower doses.2...
Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development. Benefits of saRNA saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine ...
Taking advantage of the recent innovations in systemicdelivery of short interfering RNA (siRNA) using lipid nanoparticles(LNPs), we developed a self-amplifying RNA vaccine. Here weshow that nonviral delivery of a 9-kb self-amplifying RNA encap-sulated within an LNP substantially increased ...
“Previously, we had shown our samRNA vaccine capable of driving potentially broad and durable protection through 12 months across three Phase 1 studies spanning multiple other populations and settings. The new findings announced to...
as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplif...
This is corroborated by the findings of Pepini et al., who used microarrays to measure changes in local gene expression following intramuscular injection with a self-amplifying RNA vaccine.1 They identified the upregulation of several chemokines, including Ccl2, Ccl7, Cxcl9, Cxcl10, and Cxcl1...
Self-amplifying messenger ribonucleic acid (saRNA) provides extended expression of genes of interest by encoding an alphavirus-derived RNA replicase and thus is 2–3 times larger than conventional messenger RNA. However, quality assessment of long RNA tr